# RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

> **NCT04032860** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **West China Hospital** · enrollment: 104 (actual)

## Conditions studied

- HCC
- HBV Coinfection

## Interventions

- **DRUG:** Tenofovir Disoproxil
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT04032860
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04032860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04032860, "RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04032860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*